Develop disease modifying therapies to stop or reverse the progression of neurodegenerative diseases|ANTTI VUOLANTO,Chief Executive Officer,Herantis Pharma Oyj 00:10:00
ANTTI VUOLANTOChief Executive OfficerCEO Antti Vuolanto, DSc (Tech), started in his current role in July 2022. He joined Herantis Pharma Plc in February 2018 as COO. Antti has vast experience in financing, partnering, research, development, and manufacturing of biological drugs. Previously he served as COO at Valo Therapeutics, Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.
